Companies › CytoDyn
1 active drug program in 3 registered trials: 3 Phase 2; Neurology, Infectious disease, Oncology; next expected readout Jan 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| leronlimab C-C chemokine receptor type 5 antagonist | CCR5 | Phase 2 | Metastatic Colorectal Cancer (mCRC); HIV - Human Immunodeficiency Virus; Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease | Jan 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07903441 | leronlimab | Phase 2 | HIV - Human Immunodeficiency Virus | Infectious disease | Jul 2027 |
| NCT07553338 | leronlimab | Phase 2 | Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease | Neurology | Nov 2027 |
| NCT06699836 | leronlimab | Phase 2 | Metastatic Colorectal Cancer (mCRC) | Oncology | Jan 2028 |
Cash of $16m on 2026-08-31; operating cash outflow about $31m a year; runway about 6 months at that burn, to Mar 2027; 0 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
–
Acumen Pharmaceuticals Y-mAbs Therapeutics Agenus CatalYm Alethia Biotherapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.